X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9580) 9580
Magazine Article (54) 54
Newsletter (20) 20
Book / eBook (9) 9
Book Chapter (6) 6
Book Review (3) 3
Newspaper Article (3) 3
Publication (3) 3
Reference (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6883) 6883
cardiotonic agents - therapeutic use (6777) 6777
male (4513) 4513
animals (3593) 3593
female (2993) 2993
cardiotonic agents - pharmacology (2604) 2604
cardiac & cardiovascular systems (2322) 2322
heart failure - drug therapy (2249) 2249
middle aged (1938) 1938
aged (1655) 1655
pharmacology & pharmacy (1641) 1641
rats (1556) 1556
heart failure (1343) 1343
treatment outcome (1161) 1161
cardiotonic agents - administration & dosage (1153) 1153
adult (1114) 1114
cardiotonic agents (1101) 1101
heart (1088) 1088
heart failure - physiopathology (976) 976
hemodynamics - drug effects (924) 924
mortality (915) 915
vasodilator agents - therapeutic use (733) 733
ischemia (709) 709
rats, sprague-dawley (699) 699
myocardium - metabolism (698) 698
time factors (660) 660
heart - drug effects (658) 658
risk factors (627) 627
myocardial contraction - drug effects (625) 625
cardiology (622) 622
oxidative stress (622) 622
rats, wistar (610) 610
mice (605) 605
apoptosis (603) 603
cardiotonic agents - adverse effects (603) 603
disease models, animal (596) 596
diuretics - therapeutic use (589) 589
myocardium - pathology (588) 588
analysis (550) 550
pyridazines - therapeutic use (547) 547
dose-response relationship, drug (539) 539
care and treatment (536) 536
heart rate - drug effects (533) 533
surgery (530) 530
health aspects (528) 528
dobutamine (527) 527
myocardial reperfusion injury - prevention & control (520) 520
angiotensin-converting enzyme inhibitors - therapeutic use (517) 517
digoxin - therapeutic use (516) 516
cardiac glycosides (512) 512
adrenergic beta-antagonists - therapeutic use (501) 501
heart-failure (501) 501
dobutamine - therapeutic use (476) 476
blood pressure - drug effects (470) 470
echocardiography (466) 466
cardiovascular (463) 463
medicine, general & internal (463) 463
prognosis (462) 462
electrocardiography (461) 461
drug therapy, combination (458) 458
peripheral vascular disease (456) 456
myocardial infarction (453) 453
prospective studies (452) 452
retrospective studies (450) 450
medicine & public health (446) 446
myocardial infarction - drug therapy (442) 442
hydrazones - therapeutic use (437) 437
research (435) 435
myocytes, cardiac - drug effects (434) 434
hemodynamics (425) 425
heart failure - therapy (423) 423
anesthesiology (418) 418
physiology (417) 417
cardioprotection (416) 416
drug therapy (416) 416
heart failure - mortality (402) 402
reperfusion (401) 401
aged, 80 and over (397) 397
rodents (397) 397
therapy (397) 397
cell biology (390) 390
abridged index medicus (388) 388
heart diseases (382) 382
myocardial infarction - pathology (380) 380
myocardial-infarction (378) 378
activation (376) 376
apoptosis - drug effects (364) 364
milrinone (364) 364
digoxin (361) 361
ventricular function, left - drug effects (354) 354
ischemia-reperfusion injury (351) 351
cardiac patients (349) 349
oxidative stress - drug effects (343) 343
biochemistry & molecular biology (342) 342
reperfusion injury (339) 339
cardiomyopathy (337) 337
inhibition (332) 332
myocardial reperfusion injury - metabolism (330) 330
acute myocardial-infarction (329) 329
medicine, research & experimental (329) 329
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8682) 8682
German (269) 269
French (169) 169
Russian (149) 149
Japanese (126) 126
Spanish (108) 108
Italian (101) 101
Chinese (55) 55
Portuguese (31) 31
Polish (22) 22
Dutch (18) 18
Ukrainian (14) 14
Czech (13) 13
Danish (8) 8
Hungarian (8) 8
Romanian (7) 7
Hebrew (5) 5
Lithuanian (5) 5
Turkish (5) 5
Finnish (4) 4
Norwegian (4) 4
Slovak (2) 2
Bulgarian (1) 1
Croatian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 2018, Volume 2018, Issue 1, p. CD009669
.... We have therefore summarised here the evidence on the treatment of people with CS or LCOS with different inotropic agents and vasodilative drugs... 
Simendan | C.1 Drugs | Dobutamine | Hydrazones | Nitric Oxide | Cardiac Output, Low | Cause of Death | Randomized Controlled Trials as Topic | Cardiotonic Agents | Pyridazines | Vasodilator Agents | Myocardial ischemia/coronary disease | Myocardial Infarction | Enoximone | C.1.10 Other | C. Acute Coronary Syndromes/Unstable Angina | Shock, Cardiogenic | Heart & circulation | Medicine General & Introductory Medical Sciences | Acute coronary syndrome | Shock, Cardiogenic [drug therapy; etiology] | Cardiotonic Agents [therapeutic use] | Enoximone [therapeutic use] | Cardiac Output, Low [drug therapy; etiology] | Nitric Oxide [therapeutic use] | Humans | LONG-TERM SURVIVAL | Vasodilator Agents [therapeutic use] | CARDIOPULMONARY BYPASS | Myocardial Infarction [complications] | CORONARY-ARTERY-BYPASS | Hydrazones [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Pyridazines [therapeutic use] | ACUTE HEART-FAILURE | Dobutamine [therapeutic use] | INTRAAORTIC BALLOON COUNTERPULSATION | EARLY REVASCULARIZATION | LEFT-VENTRICULAR DYSFUNCTION | ACUTE MYOCARDIAL-INFARCTION | DOUBLE-BLIND | CRITICALLY-ILL PATIENTS | Myocardial Infarction - mortality | Vasodilator Agents - therapeutic use | Middle Aged | Shock, Cardiogenic - mortality | Nitric Oxide - therapeutic use | Cardiac Output, Low - etiology | Cardiotonic Agents - therapeutic use | Myocardial Infarction - complications | Shock, Cardiogenic - drug therapy | Shock, Cardiogenic - etiology | Enoximone - therapeutic use | Cardiac Output, Low - mortality | Hydrazones - therapeutic use | Aged | Cardiac Output, Low - drug therapy | Dobutamine - therapeutic use | Pyridazines - therapeutic use
Journal Article
Postgraduate Medical Journal, ISSN 0032-5473, 12/2016, Volume 92, Issue 1094, pp. 726 - 734
An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | METAANALYSIS | RANDOMIZED-TRIAL | IN-HOSPITAL MORTALITY | DYSFUNCTION | NATRIURETIC PEPTIDE | COMBINATION | EPIDEMIOLOGY | ROSUVASTATIN | URODILATIN | Vasodilator Agents - therapeutic use | Erythropoietin - therapeutic use | United States | Humans | Calcium Channel Blockers - therapeutic use | Heart Failure - physiopathology | Aminobutyrates - therapeutic use | Cardiotonic Agents - therapeutic use | Societies, Medical | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Isosorbide Dinitrate - therapeutic use | Cardiology | Platelet Aggregation Inhibitors - therapeutic use | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Hematinics - therapeutic use | Fumarates - therapeutic use | Anticoagulants - therapeutic use | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | American Heart Association | Stroke Volume | Cardiovascular Agents - therapeutic use | Hydralazine - therapeutic use | Atrial Natriuretic Factor - therapeutic use | Iron - therapeutic use | Benzazepines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Diuretics - therapeutic use | Tetrazoles - therapeutic use | Peptide Fragments - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Practice Guidelines as Topic | Heart failure | Care and treatment | Usage | Analysis | Americans | Diagnosis | Cardiac output | Health aspects | Evidence-based medicine
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 2016, Volume 21, Issue 3, p. 264
Nowadays, there are some molecules that have shown over the years a high capacity to act against relevant pathologies such as cardiovascular disease,... 
Lung diseases | Liver disorders | ROS | Curcumin | Bioavailability | Natural compound | Antioxidant | Cardiovascular diseases | Anti-inflammatory | Cancer | lung diseases | antioxidant | OXIDATIVE STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | natural compound | CHEMOPREVENTIVE AGENT CURCUMIN | cardiovascular diseases | ALLERGIC AIRWAY INFLAMMATION | INDUCED LIPID-PEROXIDATION | I CLINICAL-TRIAL | CHEMISTRY, MULTIDISCIPLINARY | HUMAN COLORECTAL-CANCER | TUMOR-NECROSIS-FACTOR | bioavailability | liver disorders | INDUCED PULMONARY-FIBROSIS | anti-inflammatory | cancer | GLUTATHIONE-S-TRANSFERASE | NF-KAPPA-B | curcumin | Neuroprotective Agents - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Biological Availability | Curcumin - chemical synthesis | Neurodegenerative Diseases - drug therapy | Cardiotonic Agents - therapeutic use | Cardiotonic Agents - chemical synthesis | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - isolation & purification | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - chemical synthesis | Curcumin - therapeutic use | Curcumin - isolation & purification | Inflammation | Antioxidants - chemical synthesis | Neoplasms - drug therapy | Antioxidants - therapeutic use | Neuroprotective Agents - chemical synthesis | Animals | Cardiotonic Agents - isolation & purification | Neuroprotective Agents - isolation & purification | Antioxidants - isolation & purification | Anti-Inflammatory Agents - chemical synthesis | Plants, Medicinal | Antineoplastic Agents, Phytogenic - isolation & purification | Curcuma - chemistry
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2010, Volume 102, Issue 1, pp. 14 - 25
.... In addition, cytotoxic agents and targeted therapies used to treat cancer, including classic chemotherapeutic agents, monoclonal antibodies that target tyrosine kinase receptors, small molecule... 
DOXORUBICIN-INDUCED CARDIOTOXICITY | TRASTUZUMAB-RELATED CARDIOTOXICITY | ONCOLOGY | SPORADIC COLORECTAL ADENOMAS | VASCULAR-DISRUPTING AGENTS | TYROSINE KINASE INHIBITOR | N-ACETYLCYSTEINE | DAUNORUBICIN-INDUCED CYTOTOXICITY | HIGH-DOSE CHEMOTHERAPY | EARLY BREAST-CANCER | ATRIAL-FIBRILLATION | Atrial Fibrillation - chemically induced | Cardiovascular Diseases - prevention & control | Humans | Patient Care Team | Atrial Fibrillation - physiopathology | Ventricular Dysfunction, Left - chemically induced | Flavonoids - therapeutic use | Cardiotonic Agents - therapeutic use | Venous Thromboembolism - prevention & control | Cardiovascular System - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Hypertension - prevention & control | Polyphenols | Free Radical Scavengers - therapeutic use | Acetylcysteine - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Diseases - diagnosis | Heart - physiopathology | Cardiovascular Diseases - physiopathology | Stroke Volume - drug effects | Anticoagulants - therapeutic use | Cardiovascular System - drug effects | Hypertension - physiopathology | Ventricular Dysfunction, Left - physiopathology | Ventricular Dysfunction, Left - prevention & control | Cardiovascular Diseases - microbiology | Animals | Blood Coagulation - drug effects | Venous Thromboembolism - physiopathology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Phenols - therapeutic use | Venous Thromboembolism - chemically induced | Heart - drug effects | Cardiovascular Diseases - chemically induced | Atrial Fibrillation - prevention & control | Antimitotic agents | Complications and side effects | Aging | Physiological aspects | Dosage and administration | Research | Cardiovascular diseases | Antineoplastic agents | Risk factors | Index Medicus | Review
Journal Article
European heart journal, ISSN 1522-9645, 2016, Volume 38, Issue 13, pp. ehw145 - 941d
Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations 
PERMEABILITY TRANSITION PORE | PROTEIN KINASE-C | MICROVASCULAR OBSTRUCTION | PERCUTANEOUS CORONARY INTERVENTION | CARDIAC & CARDIOVASCULAR SYSTEMS | CYCLOSPORINE-A | CELLULAR BIOLOGY | BYPASS GRAFT-SURGERY | ISCHEMIA-REPERFUSION | LEFT-VENTRICULAR FUNCTION | LONG-TERM BENEFIT | Myocardial Reperfusion Injury - etiology | Nucleotides, Cyclic - metabolism | Ischemic Postconditioning - methods | Vasodilator Agents - therapeutic use | Humans | Oximes - therapeutic use | Nitric Oxide - therapeutic use | Oligopeptides - therapeutic use | Patient Selection | ST Elevation Myocardial Infarction - therapy | Cardiotonic Agents - therapeutic use | Mitochondrial Membrane Transport Proteins - physiology | Adenosine - therapeutic use | Hypothermia, Induced - methods | ST Elevation Myocardial Infarction - complications | ST Elevation Myocardial Infarction - etiology | Coronary Vessels - physiology | Metoprolol - therapeutic use | Combined Modality Therapy | Protein Kinase C - antagonists & inhibitors | Enzyme Inhibitors - therapeutic use | Nitrites - therapeutic use | Cyclosporine - therapeutic use | Myocardial Reperfusion - adverse effects | Signal Transduction - physiology | Clinical Trials as Topic - methods | Nitric Oxide - metabolism | Secosteroids - therapeutic use | Myocardial Reperfusion Injury - prevention & control | Life Sciences | Current Opinion | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Mini-Reviews in Medicinal Chemistry, ISSN 1389-5575, 04/2008, Volume 8, Issue 4, pp. 399 - 420
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 2007, Volume 14, Issue 3, pp. 315 - 338
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2014, Volume 63, Issue 12, pp. 1123 - 1133
Heart failure is a global pandemic affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in both... 
acute | heart failure | registry | hospitalization | inpatient | VENTRICULAR EJECTION FRACTION | CARDIAC & CARDIOVASCULAR SYSTEMS | QUALITY-OF-CARE | OPTIMIZE-HF REGISTRY | ORGANIZED PROGRAM | EUROBSERVATIONAL RESEARCH-PROGRAM | STROKE STATISTICS-2012 UPDATE | INITIATE LIFESAVING TREATMENT | ONE-YEAR MORTALITY | PHYSICIAN FOLLOW-UP | PRESERVED SYSTOLIC FUNCTION | Age Distribution | Vasodilator Agents - therapeutic use | Anemia - epidemiology | United States | Humans | Catheterization, Swan-Ganz - utilization | Male | Dyspnea - etiology | Cardiotonic Agents - therapeutic use | Heart Failure - therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Electrocardiography | Female | Registries | Coronary Angiography - utilization | Heart Failure - diagnosis | Heart Failure - epidemiology | Heart Failure - etiology | Drug Utilization - statistics & numerical data | Length of Stay - statistics & numerical data | Adrenergic beta-Antagonists - therapeutic use | Hyponatremia - epidemiology | Cardiac Resynchronization Therapy - utilization | Echocardiography | Glomerular Filtration Rate | Hospital Mortality | Comorbidity | Europe | Defibrillators, Implantable - utilization | Hospitalization | Evidence-Based Medicine | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Quality Improvement | Asia | Natriuretic Peptides - analysis | Sex Distribution | Diuretics - therapeutic use | Aged | Angiotensin Receptor Antagonists - therapeutic use | Heart failure | Medical colleges | Medical research | Mortality | Therapeutics | Economic aspects | Medicine, Experimental | Natriuretic peptides | Homeopathy | Materia medica and therapeutics
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 11/2010, Volume 17, Issue 31, pp. 3632 - 3642
Vanadium is a trace element present in practically all cells in plants and animals. While the essentiality of vanadium for human beings remains to be well... 
Insuinmimics |